W
WAVEMAN · COMPANY
CING · Cingulate Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

CING

Cingulate Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001862150
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
29
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
29 funds added or opened last quarter
below 64% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
10.8% of shares outstanding short · 10.0 days to cover · settled 2026-07-31
more than 79% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
29 funds added or opened positions in the latest 13F quarter, of 40 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +39.9%
+39.9%12M
-11%+64%+138%+213%2025-092025-102025-122026-032026-052026-072026-09 2026-02-13 · Hargroves Thomas Jeffrey bought $490.3K2026-02-06 · Werth Peter J. bought $98.1K2026-02-06 · Schaffer Shane J. bought $34.3K2026-02-06 · Callahan Jennifer L. bought $24.5K2026-02-06 · Brams Matthew bought $9.8K2026-02-09 · Falcon Creek Capital Advisor LLC filed a 5%+ stake (19.9%)2026-02-09 · Falcon Creek Technology Fund I, LP filed a 5%+ stake (3.3%)2026-02-09 · Ginkgo Capital Global Fund SPC - Xtalpi AI Fund SP filed a 5%+ stake (16.6%)
INSIDER BUY13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows 29 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Cingulate Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
Hargroves Thomas Jeffrey
Director
BUY
2026-02-13
97,276.0
$490.3K
Werth Peter J.
Director
BUY
2026-02-06
19,455.0
$98.1K
Callahan Jennifer L.
SVP and CFO
BUY
2026-02-06
4,864.0
$24.5K
Schaffer Shane J.
Chief Executive Officer
BUY
2026-02-06
6,809.0
$34.3K
Brams Matthew
EVP and Chief Medical Officer
BUY
2026-02-06
1,946.0
$9.8K
44 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 39 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
VANGUARD CAPITAL MANAGEMENT LLC
570,873.0 sh
$3.1M
RAYMOND JAMES FINANCIAL INC
166,898.0 sh
$912.9K
Chicago Partners Investment Group LLC
188,429.0 sh
$912.0K
Kestra Advisory Services, LLC
151,500.0 sh
$828.7K
GEODE CAPITAL MANAGEMENT, LLC
144,636.0 sh
$791.4K
5%+ owners
13D = intent to influence · 13G = passive
Falcon Creek Capital Advisor LLC
ACTIVIST 13D · 2026-02-09
19.9%
Falcon Creek Technology Fund I, LP
ACTIVIST 13D · 2026-02-09
3.3%
Ginkgo Capital Global Fund SPC - Xtalpi AI Fund SP
ACTIVIST 13D · 2026-02-09
16.6%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
VANGUARD EXTENDED MARKET INDEX FUND
$569.6K POSITION · AS OF 2026-03-31
0.0%
Fidelity Extended Market Index Fund
$234.9K POSITION · AS OF 2026-02-28
0.0%
Fidelity Total Market Index Fund
$141.3K POSITION · AS OF 2026-02-28
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$1.3M POSITION · AS OF 2026-03-31
0.0%
VANGUARD BALANCED INDEX FUND
$34.8K POSITION · AS OF 2026-03-31
0.0%
Fidelity Series Total Market Index Fund
$49.3K POSITION · AS OF 2026-02-28
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-19.9M$-15.6M$-22.8M$-17.5M
NET INCOME$-22.4M$-16.6M$-23.5M$-17.7M
EPS (DILUTED)-4.44-10.86-311.99-29.35
OPERATING CASH FLOW$-17.2M$-18.5M$-15.0M$-15.9M
CASH$11.0M$12.2M$52.4K$5.4M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →